Shanghai Fosun Pharmaceutical is set to launch a $600 million Hong Kong share financing as cited by sources with knowledge of the deal.
This financing deal, which was earlier set to raise as much as $800 million, would be the first major stock sale in Hong Kong after a drought of nearly three months in offerings.
Shanghai Fosun Pharmaceutical is a subsidiary of Fosun International, one of the country’s largest conglomerates.
China International Capital Corp (CICC), Deutsche Bank , JPMorgan and UBS are handling the financing offering.
For further deal information visit Current Agreements (subscription required)
Read: more on financing deals in pharma, biotech, life science partnering deal news, insights and glossary
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value
View: Current Partnering’s Financing Scorecard – view top life science financing deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity